Management of Acute Podagra (Gout)
For acute podagra, treat immediately with corticosteroids as first-line therapy (prednisolone 35 mg daily for 5 days), NSAIDs, or low-dose colchicine (1.2 mg followed by 0.6 mg one hour later), and reserve long-term urate-lowering therapy only for patients with recurrent attacks (≥2 per year) or problematic gout features. 1
Acute Attack Management
First-Line Treatment Options
All three medication classes are equally effective for acute pain relief, but corticosteroids should be prioritized when no contraindications exist because they are safer, equally effective as NSAIDs, and low-cost 1. The choice depends on patient-specific contraindications:
Corticosteroids (Preferred):
- Prednisolone 35 mg daily for 5 days 1
- Contraindicated only in systemic fungal infections
- Avoid in uncontrolled diabetes due to glucose elevation
- Short-term use minimizes risks of dysphoria, mood disorders, immune suppression
NSAIDs:
- Any NSAID is acceptable—indomethacin has no superiority over naproxen or ibuprofen 1
- Contraindicated in renal disease, heart failure, or cirrhosis
- Risk of GI bleeding, ulcers, and perforations
Low-Dose Colchicine:
- 1.2 mg loading dose, then 0.6 mg one hour later (total 1.8 mg on day 1) 1
- High-dose regimens offer no additional benefit and cause more GI side effects
- Must initiate within 12 hours of symptom onset for optimal efficacy 2
- Contraindicated with severe renal/hepatic impairment or concurrent use of strong CYP3A4/P-glycoprotein inhibitors (cyclosporine, clarithromycin) 2
- More expensive than NSAIDs or corticosteroids 1
Critical Timing
Patients should be educated to self-medicate at the first warning symptoms of a flare 2. Early treatment is essential for effectiveness.
Long-Term Urate-Lowering Therapy (ULT)
When NOT to Start ULT
Do not initiate ULT after a first gout attack or in patients with infrequent attacks (<2 per year) 1. This is a strong recommendation because:
- Benefits of long-term ULT (≥12 months) are unproven in these patients
- Many patients have no or few recurrences without treatment
- ULT can be reconsidered if attacks become frequent
When to Consider ULT
Engage in shared decision-making for patients with:
- ≥2 gout episodes per year (recurrent gout)
- Tophi formation
- Chronic kidney disease
- Urolithiasis
- Serum urate >8 mg/dL (476 µmol/L)—these patients face higher recurrence risk 1
ULT Initiation Strategy
When starting ULT after shared decision-making 1:
Medication Options:
- Allopurinol 300 mg/day and febuxostat 40 mg/day are equally effective at lowering serum urate 1
- Allopurinol preferred due to lower cost
- Febuxostat causes more abdominal pain, diarrhea, musculoskeletal pain
- Allopurinol causes more rash
Mandatory Flare Prophylaxis:
- Continue prophylaxis for >8 weeks (ideally 6 months) when starting ULT 1, 2
- Use low-dose colchicine (0.5-1 mg/day) or low-dose NSAIDs 1
- This prevents paradoxical flares during the first 6 months of ULT
- ULT reduces gout attacks only after 1 year, not within first 6 months 1
Treat-to-Target Approach
While the ACP guidelines note insufficient evidence for routine serum urate monitoring 1, recent 2025 data suggests achieving serum urate <6 mg/dL reduces cardiovascular events and gout flares, with even greater benefit at <5 mg/dL 3. The EULAR guidelines support treating to a serum urate target 2.
Common Pitfalls to Avoid
- Never use high-dose colchicine regimens—they cause unnecessary GI toxicity without added benefit 1
- Don't assume indomethacin is superior—any NSAID works equally well 1
- Don't start ULT during an acute flare—wait until the attack resolves
- Don't start ULT without prophylaxis—this triggers more flares and poor adherence
- Don't prescribe ULT after a single attack—most patients don't need it 1
Patient Education Priority
Every patient must understand that gout is curable through lifelong serum urate lowering, but this requires adherence to ULT when indicated 2. Education increases adherence rates to 92% at 12 months 2.